- Ibritumomab tiuxetan
primary sources date October 2009 Drugbox Verifiedfields changed verifiedrevid 458274054 image Ibritumomab tiuxetan structure.svg Monoclonal antibody data type mab mab type mab source o target CD20 Clinical data tradename Zevalin licence US Ibritumomab Drugs.com drugs.com monograph ibritumomab tiuxetan ... EBI ChEMBL 1201606 Chemical data Ibritumomab tiuxetan , sold under the trade name Zevalin , is a monoclonal ... never exceeds 32 mCi. Ibritumomab tiuxetan is administered by intravenous infusion which usually lasts around 10 minutes. Only acrylic shielding is needed, not lead. Efficacy Treatment with ibritumomab ... was 34 20 , comparing ibritumomab to rituximab. ref http www.zevalin.com HealthCarePro efficacy.htm Ibritumomab Efficacy ref Recently, extended follow up data for the ZEVALIN 90Y ibritumomab tiuxetan ... of Biogen Idec , ibritumomab tiuxetan was the first radioimmunotherapy drug approved by the Food and Drug ... agents Category Monoclonal antibodies for tumors de Ibritumomab Tiuxetan it Ibritumomab tiuxetan ... uses the monoclonal mouse IgG IgG1 antibody ibritumomab pronounced as ih bri TYOO mo mab ref http body.aol.com drugs ibritumomab Ibritumomab Pronunciation ref in conjunction with the chelator tiuxetan, to which a radioactive isotope either yttrium 90 or indium 111 is added. Tiuxetan is a modified ... to develop from lymphoid stem cell s. Administration In order to qualify for ibritumomab, a patient ... Ibritumomab Indications ref and 15 bone marrow cellularity. Since ibritumomab is known to cause cytopenia ... mouse antibodies HAMA . Having bulky disease does not disqualify a patient. The ibritumomab regimen ... to ibritumomab, but without the attached radioisotope , and showed very promising results for patients ... demonstrated the continued improvement in progression free survival PFS following ibritumomab consolidation ... line therapy over chemotherapy alone. Additionally, ibritumomab consolidation did not adversely ... that rituximab followed by single agent ibritumomab in a front line setting for patients with MALT ... more details
|
- List of drugs: Y
List of drugs Y Y y Drospirenone Yasmin Yervoy ipilimumab Yohimbine Yocon Yutopar yohimbic acid International Nonproprietary Name INN yttrium Y 90 clivatuzumab tetraxetan United States Adopted Name USAN ibritumomab tiuxetan yttrium Y 90 ibritumomab tiuxetan International Nonproprietary Name INN ... more details
|
- ATC code V10
ATC codes lead V 10 Therapeutic radiopharmaceuticals anchor V10A V10A Anti inflammatory agents anchor V10AA V10AA Yttrium Yttrium 90 sup 90 sup Y compounds V10AA01 Yttrium sup 90 sup Y citrate colloid V10AA02 Yttrium sup 90 sup Y ferrihydroxide colloid V10AA03 Yttrium sup 90 sup Y silicate colloid anchor V10AX V10AX Other anti inflammatory therapeutic radiopharmaceuticals V10AX01 Phosphorus Phosphorus 32 sup 32 sup P chromicphosphate colloid V10AX02 Samarium Samarium 153 sup 153 sup Sm hydroxyapatite colloid V10AX03 Dysprosium Dysprosium 165 sup 165 sup Dy colloid V10AX04 Erbium Erbium 169 sup 169 sup Er citrate colloid V10AX05 Rhenium Rhenium 186 sup 186 sup Re sulfide colloid V10AX06 Gold Gold 198 sup 198 sup Au colloidal anchor V10B V10B Pain palliation bone seeking agent s anchor V10BX V10BX Various pain palliation radiopharmaceuticals V10BX01 Strontium Strontium 89 sup 89 sup Sr chloride V10BX02 Samarium 153Sm lexidronam Samarium sup 153 sup Sm lexidronam V10BX03 Rhenium sup 186 sup Re etidronic acid anchor V10X V10X Other therapeutic radiopharmaceuticals anchor V10XA V10XA Iodine Iodine 131 sup 131 sup I compounds V10XA01 Sodium iodide sup 131 sup I V10XA02 Iobenguane 131I Iobenguane sup 131 sup I V10XA53 Tositumomab Tositumomab iodine sup 131 sup I tositumomab anchor V10XX V10XX Various therapeutic radiopharmaceuticals V10XX01 Sodium phosphate sup 32 sup P V10XX02 Ibritumomab tiuxetan 90Y Ibritumomab tiuxetan sup 90 sup Y References Reflist Therapeutic radiopharmaceuticals Category ATC codes V10 ca Codi ATC V10 ko ATC V10 hu ATC V10 Ter pi ban haszn lt radiofarmakonok ro Cod ATC V10 sv ATC kod V10 Terapeutiska radiofarmaka th ATC V10 ... more details
|
- Tositumomab
Drugbox Verifiedfields changed verifiedrevid 470611959 Monoclonal antibody data type mab mab type mab source o target CD20 Clinical data tradename Drugs.com drugs.com monograph tositumomab MedlinePlus a609013 pregnancy AU A B1 B2 B3 C D X pregnancy US A B C D X legal AU Unscheduled S2 S4 S8 legal UK GSL P POM CD legal US OTC Rx only Identifiers ChemSpiderID Ref chemspidercite correct chemspider ChemSpiderID NA CAS number Ref cascite correct ?? CAS number 192391 48 3 ATC prefix V10 ATC suffix XA53 ATC supplemental sequential regimen with sup 131 sup I form DrugBank Ref drugbankcite correct drugbank DrugBank DB00081 UNII Ref fdacite correct FDA UNII 0343IGH41U KEGG Ref keggcite correct kegg KEGG D08622 ChEMBL Ref ebicite changed EBI ChEMBL 1201604 Chemical data C 6416 H 9874 N 1688 O 1987 S 44 molecular weight 143859.7 g mol Tositumomab is a drug for the treatment of follicular lymphoma . It is a IgG 2a anti CD20 monoclonal antibody derived from immortalized mouse cells. Tositumomab is applied in a sequential infusion followed by iodine sup 131 sup I tositumomab , which is the same antibody covalently bound to the radionuclide iodine 131 sup 131 sup I . ref http us.gsk.com products assets us bexxar.pdf Bexxar Prescribing Information ref sup 131 sup I emits both beta radiation beta and gamma radiation and decays with a half life of 8 days. Clinical trials have established the efficacy of the tositumomab iodine sup 131 sup I tositumomab regimen in patients with relapsed or chemotherapy rituxan refractory follicular lymphoma. This drug combination is manufactured by Corixa now GlaxoSmithKline . It sells in the U.S. under the trade name Bexxar . Bexxar was developed by Dr. Mark Kaminski and Dr. Richard Wahl. There is some evidence that it may cause a smaller decrease in platelet counts than ibritumomab tiuxetan does. ref name pmid17942813 Cite journal author Jacene HA, Filice R, Kasecamp W, Wahl RL title Comparison of 90Y ibritumomab tiuxetan and 131I tositumomab in clini ... more details
|
- Radioimmunotherapy
Interventions infobox Name PAGENAME Image Caption ICD10 ICD9 ICD9proc 92.28 MeshID D016499 OtherCodes Radioimmunotherapy RIT uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell ref Milenic DE, Brady ED and Brechbiel MW. Antibody targeted radiation cancer therapy. Nature Rev Drug Discovery 2004 3 488 98. ref . In cancer therapy, an antibody with specificity for a tumor associated antigen is used to deliver a lethal dose of radiation to the tumor cells. The ability for the antibody to specifically bind to a tumor associated antigen increases the dose delivered to the tumor cells while decreasing the dose to normal tissues. By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal cells. History of available agents expand list date February 2011 class wikitable Food and Drug Administration United States U.S. FDA approval Name Description 2002 ref http www.fda.gov bbs topics ANSWERS 2002 ANS01138.html Fda Approves First Radiopharmaceutical Product To Treat Non Hodgkin S Lymphoma Bot generated title dead link date May 2011 ref ref Rao AV, Akabani G, Rizzieri DA. Radioimmunotherapy for Non Hodgkin s Lymphoma. Clin Med Res. 2005 Aug 3 3 157 65. ref Ibritumomab tiuxetan Zevalin monoclonal antibody anti CD20 conjugated to a molecule that chelates Yttrium 90 . 2003 ref http www.fda.gov cder biologics products tosicor062703.htm Tositumomab and Iodine I 131 Tositumomab Product Approval Information Licensing Action Bot generated title dead link date May 2011 ref Tositumomab Iodine sup 131 sup I tositumomab Bexxar links a molecule containing Iodine 131 to the monoclonal antibody anti CD20 . These medications were the first agents of radioimmunotherapy, and they were approved for the treatment of refractory non Hodgkins lymphoma . This means they are used in patients whose lymphoma is refractory to conventional chemotherapy and the monoclonal antibody rituximab . Actinium Ph ... more details
|
- Pentetic acid
scaffold for metal ions. In ibritumomab tiuxetan , the chelator tiuxetan is a modified ... more details
|
- List of drugs: Z
List of drugs Z Z z Z PAK za zabicipril International Nonproprietary Name INN zabiciprilat International Nonproprietary Name INN zabofloxacin International Nonproprietary Name INN zacopride International Nonproprietary Name INN Zaditen Zaditor zafirlukast International Nonproprietary Name INN zafuleptine International Nonproprietary Name INN sparfloxacin Zagam zalcitabine International Nonproprietary Name INN zaldaride International Nonproprietary Name INN zaleplon International Nonproprietary Name INN zalospirone International Nonproprietary Name INN zalutumumab International Nonproprietary Name INN zaltidine International Nonproprietary Name INN zaltoprofen International Nonproprietary Name INN zamifenacin International Nonproprietary Name INN Zanaflex zanamivir International Nonproprietary Name INN zankiren International Nonproprietary Name INN zanolimumab United States Adopted Name USAN Zanosar Pharmacia & Upjohn Company zanoterone International Nonproprietary Name INN Zantac Zantryl zapizolam International Nonproprietary Name INN zaprinast International Nonproprietary Name INN Zapzyt zardaverine International Nonproprietary Name INN Zarontin Zaroxolyn zatebradine International Nonproprietary Name INN zatosetron International Nonproprietary Name INN zaurategrast International Nonproprietary Name INN Zavesca Zaxopam ze Zebeta Zefazone Zegerid Zelnorm Zemaira Zemplar Zemuron Daclizumab Zenapax zenarestat International Nonproprietary Name INN zeniplatin International Nonproprietary Name INN zepastine International Nonproprietary Name INN Zephiran Zephrex zeranol International Nonproprietary Name INN Zerit Zestoretic Zestril Zetacet Zetar Zetia zetidoline International Nonproprietary Name INN Zetran Ibritumomab tiuxetan Zevalin Biogen Idec zi Ziac Ziagen GlaxoSmithKline . Redirects to abacavir . Ziba Rx zibotentan United States Adopted Name USAN zibrofusidic acid International Nonproprietary Name INN ziconotide International Nonproprietary Name INN zicronapine Inter ... more details
|
- Cancer immunotherapy
clearance from the body. Ibritumomab tiuxetan Ibritumomab tiuxetan is a murine antibody chemically ... and short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first line treatment for patients ... ozogamicin Mylotarg 2000 humanized CD33 acute myelogenous leukemia with calicheamicin Ibritumomab tiuxetan Zevalin 2002 murine CD20 non Hodgkin lymphoma with Yttrium yttrium 90 or Indium indium 111 ... a lethal radioactive dose directly to the target cell, which has been utilized in the case of the Ibritumomab tiuxetan Zevalin therapeutic. A third strategy is to deliver a lethal chemical dose to the target ... more details
|
- Bendamustine
, prednisone , rituximab , vincristine and sup 90 sup Y ibritumomab tiuxetan . One combination ... more details
|
- Biogen Idec
, 2007, Biogen Idec sold the U.S. rights for Zevalin ibritumomab tiuxetan , another treatment ... more details
|
- Index of oncology articles
cancer incisional biopsy incomplete Freund s adjuvant indinavir ibritumomab tiuxetan indium In 111 ibritumomab tiuxetan indium In 111 pentetreotide indole 3 carbinol indolent lymphoma indometacin ... x ray therapy xenograft xeroderma pigmentosum xerogram xerostomia XK469 XR9576 Y YM598 ibritumomab tiuxetan yttrium Y 90 ibritumomab tiuxetan yttrium Y 90 SMT 487 yttrium Y 90 DOTA tyr3 octreotide Z ... more details
|
- Nuclear medicine physician
with sup 90 sup Y ibritumomab tiuxetan Zevalin & sup 131 sup I tositumomab Bexxar therapy ... more details
|
- CD20
ref Clinical significance CD20 is the target of the monoclonal antibodies mAb rituximab , Ibritumomab tiuxetan , and tositumomab , which are all active agents in the treatment of all B cell lymphoma ... more details
|
- Monoclonal antibody therapy
TNF alpha inihibitor Rheumatoid arthritis, Psoriatic arthritis, and Ankylosing spondylitis Ibritumomab tiuxetan Zevalin 2002 murine CD20 Non Hodgkin lymphoma with Yttrium yttrium 90 or Indium indium ... more details
|
- Germinal center B-cell like diffuse large B-cell lymphoma
Tositumomab Bexxar . Anti CD20 conjugated with radionuclide iodine 131 Ibritumomab tiuxetan Zevalin ... more details
|
- Nuclear medicine
and thyroid cancer Yttrium 90 ibritumomab tiuxetan Zevalin and Iodine 131 tositumomab Bexxar refractory ... more details
|
- Hairy cell leukemia
B cell destroying monoclonal antibodies such as Alemtuzumab , Ibritumomab tiuxetan and I 131 Tositumomab ... more details
|
- List of monoclonal antibodies
HIV infection Ibritumomab tiuxetan Zevalin mab mouse CD20 non Hodgkin s lymphoma Icrucumab ref name ... more details
|
- Yttrium
such as Yttrium Y 90 DOTA tyr3 octreotide and Yttrium Y 90 ibritumomab tiuxetan for the treatment ... more details
|
Encyclopedia
top
